Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYT9B4
|
|||
| Drug Name |
AL002
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Triggering receptor expressed on monocytes 2 (TREM2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04592874) A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med. 2020 Sep 7;217(9):e20200785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.